Henry Schein
HSIC
$84.01
-0.73%
Henry Schein Inc. is a global healthcare solutions company that distributes dental and medical supplies, equipment, and value-added services to office-based practitioners and alternative care sites, operating primarily through its Global Distribution and Value-Added Services segment, which generated $2.95 billion of the most recent quarter's $3.37 billion in revenue. As one of the largest distributors in a highly fragmented medical and dental products market, Henry Schein occupies a scale-driven, relationship-intensive position that is distinct from manufacturers and pure-play technology vendors, with a growing Technology segment ($221 million in quarterly revenue) that includes practice management software and digital workflow tools. The current investor narrative centers on whether the company can sustain its mid-single-digit revenue growth (6.3% year-over-year in the March 2026 quarter) while defending margins against distributor competition and input cost pressure, particularly as gross margin has oscillated between 28.7% and 31.8% over recent quarters. Attention is also focused on the company's capital allocation, including aggressive share repurchases ($125 million in Q1 2026 alone) and debt reduction, which have shrunk the share count but contributed to a negative free cash flow quarter, raising questions about the durability of cash generation amid working capital swings.…
HSIC
Henry Schein
$84.01
Investment Opinion: Should I buy HSIC Today?
Based on the synthesis of analyst consensus, valuation, and growth trajectory, HSIC earns a Buy rating. The core thesis is that HSIC offers a compelling risk/reward with a forward PE of 14.04x, 6.3% revenue growth, and a 15.8% upside to the average analyst target of $97.27. The consensus recommendation of buy from 15 analysts, with a mean rating of 2.375, supports this view.\n\nSupporting evidence includes: 1) Revenue growth of 6.3% YoY in Q1 2026, accelerating from 1.5% in Q4 2025; 2) Forward PE of 14.04x, which is below the trailing PE of 23.14x and suggests undervaluation relative to earnings growth; 3) ROE of 12.27% and ROA of 4.39%, indicating efficient capital use; 4) TTM free cash flow of $431 million, despite a negative Q1, providing capacity for buybacks and debt reduction; and 5) Analyst target upside of 15.8% to $97.27, with a high target of $110. The PS ratio of 0.70 and EV/Sales of 1.08 are low for a healthcare distributor, implying the market is not paying a premium.\n\nKey risks that could invalidate the thesis include: 1) Gross margin falling below 28%, which would pressure earnings; 2) Revenue growth decelerating below 4%, which would challenge the growth narrative; and 3) Free cash flow remaining negative, limiting financial flexibility. The rating would upgrade to Strong Buy if gross margins stabilize above 30% and revenue growth exceeds 7%, or downgrade to Hold if revenue growth falls below 4% or if debt-to-equity rises above 1.3x. Relative to its history and peers, HSIC appears undervalued on a forward earnings basis, trading at 14x forward PE versus a trailing PE of 23x, suggesting the market expects earnings growth to continue.
Sign up to view all
HSIC 12-Month Price Forecast
HSIC presents a balanced risk/reward with a bullish tilt. The company's revenue growth is accelerating, and the forward valuation is undemanding at 14x earnings. Analyst sentiment is positive, with a consensus buy rating and significant upside to the average target. However, margin volatility and negative free cash flow in Q1 2026 are concerns that warrant a medium confidence level. The stock's low beta and essential healthcare distribution business provide downside protection. I would upgrade to high confidence if gross margins stabilize above 30% and free cash flow turns consistently positive. Conversely, a downgrade to neutral would occur if revenue growth falls below 4% or if debt-to-equity exceeds 1.3x.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Henry Schein's 12-month outlook, with a consensus price target around $97.27 and implied upside of +15.8% versus the current price.
Average Target
$97.27
0 analysts
Implied Upside
+15.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$64 - $110
Analyst target range
Bulls vs Bears: HSIC Investment Factors
The bull case rests on HSIC's accelerating revenue growth (6.3% YoY), attractive forward valuation (14.0x PE), and strong analyst support (15 buy ratings, $97.27 average target). The bear case highlights margin volatility (gross margin range of 28.7%-31.8%), negative Q1 free cash flow, and high leverage (D/E of 1.14x). Currently, the bull evidence appears stronger given the revenue acceleration, share buybacks, and significant analyst upside, but the margin and cash flow trends are critical to monitor. The single most important tension is whether HSIC can sustain its revenue growth while stabilizing gross margins above 30%, which would justify the forward earnings multiple and drive the stock toward analyst targets. If margins continue to oscillate and free cash flow remains volatile, the bear case could gain traction.
Bullish
- Analyst consensus buy with 15.8% upside: 15 analysts rate HSIC a buy with an average target price of $97.27, implying 15.8% upside from the current $84.01. The high target of $110 suggests 30.9% upside if execution improves, while the low target of $64 is 23.8% below current levels.
- Revenue growth accelerating to 6.3% YoY: Q1 2026 revenue grew 6.3% year-over-year to $3.368 billion, up from $3.168 billion in Q1 2025. This marks a meaningful acceleration from the 1.5% YoY growth in Q4 2025 and supports the mid-single-digit growth narrative.
- Forward PE of 14.0x is undemanding: HSIC trades at a forward PE of 14.04x based on estimated EPS of $6.975, well below the trailing PE of 23.14x. The PEG ratio of 3.23 appears elevated but reflects the low forward multiple relative to near-term growth, suggesting the market is pricing in modest expectations.
- Strong ROE of 12.3% and low beta: Return on equity of 12.27% and return on assets of 4.39% demonstrate efficient capital deployment. The beta of 0.843 indicates lower volatility than the broader market, making HSIC a defensive healthcare distribution play.
Bearish
- Negative free cash flow in Q1 2026: Despite TTM free cash flow of $431 million, Q1 2026 saw negative free cash flow due to working capital swings and $125 million in buybacks. This raises questions about the sustainability of cash generation and the pace of debt reduction.
- Gross margin volatility and compression: Gross margin has oscillated between 28.7% and 31.8% over recent quarters, with Q4 2025 at 28.9% and Q1 2026 at 31.8%. The trailing twelve-month gross margin of 29.1% is below the 30.5% seen in Q2 2024, indicating margin pressure.
- High debt-to-equity of 1.14x: Debt-to-equity of 1.14x and interest expense of $39 million in Q1 2026 (up from $35 million in Q1 2025) highlight a leveraged balance sheet. With a current ratio of 1.38, liquidity is adequate but not robust.
- Underperformance vs. S&P 500 recently: HSIC has underperformed the S&P 500 by 6.62% over the past month and 4.81% year-to-date, despite a 30.1% one-year gain. The recent relative weakness suggests waning momentum and possible sector rotation away from healthcare distributors.
HSIC Technical Analysis
Beta
0.84
0.84x market volatility
Max Drawdown
-17.2%
Largest decline past year
52-Week Range
$62-$92
Price range past year
Annual Return
+30.1%
Cumulative gain past year
| Period | HSIC Return | S&P 500 |
|---|---|---|
| 1m | -4.5% | +1.9% |
| 3m | -0.5% | +3.9% |
| 6m | +11.5% | +12.1% |
| 1y | +30.1% | +19.2% |
| ytd | +9.4% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HSIC Fundamental Analysis
Quarterly Revenue
$3.4B
2026-03
Revenue YoY Growth
+6.3%
YoY Comparison
Gross Margin
31.8%
Latest Quarter
Free Cash Flow
$431000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HSIC Overvalued?
PE
23.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 15x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks for HSIC are centered on its leveraged balance sheet and margin volatility. Debt-to-equity stands at 1.14x, with interest expense of $39 million in Q1 2026 consuming a meaningful portion of operating income ($182 million). The company's net margin of 3.02% and operating margin of 5.75% are thin, leaving little buffer against cost inflation or pricing pressure. Additionally, gross margin has fluctuated between 28.7% and 31.8% over the past five quarters, indicating inconsistent cost management or product mix shifts. The negative free cash flow in Q1 2026, despite TTM FCF of $431 million, raises concerns about working capital efficiency and the sustainability of buybacks and debt reduction. Revenue concentration in the Global Distribution and Value-Added Services segment ($2.95 billion of $3.37 billion in Q1 2026 revenue) exposes the company to trends in dental and medical office spending, which are sensitive to economic cycles.\n\nMarket and competitive risks include valuation compression if growth slows or margins disappoint. HSIC trades at a forward PE of 14.04x, which is not demanding, but the PEG ratio of 3.23 suggests the market may be pricing in limited growth. The beta of 0.843 indicates lower volatility than the market, but the stock has underperformed the S&P 500 by 6.62% over the past month and 4.81% year-to-date, reflecting recent weakness. Competition in the fragmented medical and dental distribution market is intense, with rivals potentially pressuring pricing and margins. Regulatory changes in healthcare reimbursement or drug pricing could impact demand for dental and medical supplies. Macro sensitivity is moderate given the defensive nature of healthcare, but a recession could reduce elective dental procedures and capital equipment purchases.\n\nThe worst-case scenario would involve a combination of margin compression, revenue deceleration, and increased leverage. If gross margins fall below 28% and revenue growth stalls, earnings could decline, leading to multiple compression. The 52-week low of $61.95 represents a 26.3% downside from the current price of $84.01, while the analyst low target of $64 implies 23.8% downside. A more severe scenario, such as a recession reducing dental visits and capital spending, could push the stock toward the 52-week low, resulting in a loss of approximately 26% from current levels. The max drawdown of 17.23% over the past 180 days also highlights the stock's vulnerability to sharp declines during adverse conditions.
FAQ
The key risks include: 1) Financial risk: High debt-to-equity of 1.14x and interest expense of $39 million in Q1 2026, which could strain profitability if rates rise. 2) Operational risk: Gross margin volatility (28.7%-31.8% range) and negative free cash flow in Q1 2026, which may limit buybacks and debt reduction. 3) Market risk: Recent underperformance vs. the S&P 500 (-6.62% over one month) and a beta of 0.843, indicating sensitivity to market downturns. 4) Competitive risk: Intense competition in the fragmented medical distribution market could pressure pricing and margins. The most severe risk is a combination of margin compression and revenue deceleration, which could push the stock toward the 52-week low of $61.95, a 26.3% downside.
The 12-month forecast includes three scenarios: Bull case (25% probability) with a target range of $97-$110, driven by margin stabilization and revenue acceleration; Base case (55% probability) with a target range of $90-$97, assuming mid-single-digit growth and stable margins; Bear case (20% probability) with a target range of $64-$75, triggered by margin compression and revenue deceleration. The base case is most likely, aligning with the analyst average target of $97.27. The key assumption is that gross margins stabilize around 29-30% and revenue grows 5-6%. If the company beats on margins, the bull case could materialize; if it misses, the bear case could unfold.
HSIC appears undervalued on a forward earnings basis, trading at a forward PE of 14.04x compared to a trailing PE of 23.14x. The PS ratio of 0.70 and EV/Sales of 1.08 are low for a healthcare distributor, suggesting the market is not pricing in significant growth. The PEG ratio of 3.23 is elevated, but this reflects the low forward multiple relative to near-term growth. Compared to its own history, the forward PE is below the trailing average, indicating potential undervaluation. The market seems to expect modest earnings growth, and if the company delivers, the multiple could expand. Relative to peers, HSIC trades at a discount, making it an attractive value proposition.
HSIC appears to be a good buy for investors with a medium to long-term horizon, given the 15.8% upside to the average analyst target of $97.27 and a forward PE of 14.04x. The company's revenue growth of 6.3% YoY in Q1 2026 and ROE of 12.27% support a positive outlook. However, the negative free cash flow in Q1 2026 and gross margin volatility are risks. The stock is suitable for those seeking defensive healthcare exposure with low beta (0.843). It may not be ideal for short-term traders due to recent underperformance vs. the S&P 500 (-6.62% over one month). Overall, a buy for patient investors who can tolerate modest volatility.
HSIC is more suitable for long-term investment (minimum 2-3 years) given its stable business model, low beta (0.843), and growth potential in healthcare distribution. The company does not pay a dividend, so returns depend on capital appreciation. Short-term trading is less attractive due to recent underperformance vs. the S&P 500 and the lack of near-term catalysts. The stock's 52-week range of $61.95-$92.18 and max drawdown of 17.23% suggest moderate volatility. Long-term investors can benefit from revenue growth, share buybacks, and potential multiple expansion. A holding period of at least 2 years allows time for margin stabilization and debt reduction to play out.